

**Complete listing of claims:**

1. (Currently amended) A method of improving the pharmacokinetic profile of administering  
~~a drug for which the major clearance mechanism in humans is CYP2D6-mediated oxidative~~  
~~biotransformation and that is (2S,3S)-2-phenyl-3-(2-methoxy-5-~~  
~~trifluoromethoxyphenyl)methylamino-piperidine, or a pharmaceutically acceptable salt thereof, the~~  
method comprising administering (2S,3S)-2-phenyl-3-(2-methoxy-5-  
trifluoromethoxyphenyl)methylamino-piperidine, or the pharmaceutically acceptable salt thereof,  
in combination with a CYP2D6 inhibitor, ~~or a pharmaceutically acceptable salt thereof, to a~~  
~~human in need of the intended pharmaceutical activity of such drug, wherein said drug and said~~  
~~CYP2D6 inhibitor are not the same compound selected from the group consisting of quinidine,~~  
ajmalacine and pharmaceutically acceptable salts thereof.

2-23. (cancelled)